About Abcam
Abcam is a Healthcare company based in Cambridge (United Kingdom) founded in 1998 by Avner Dahan and Tony Kouzarides, and was acquired by Danaher in August 2023. Biological reagents and antibodies are developed for life science research. Abcam has raised $78.8 million across 6 funding rounds from investors including Danaher, HHS and National Science Foundation. Abcam has completed 12 acquisitions, including Ascent Scientific, AxioMx and BioVision. Its website abcam.com draws about 603 thousand monthly visits. Abcam offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified. Its legal entity is ABCAM LIMITED.
Company details
Abcam was founded in 1998 in Cambridge, United Kingdom, within the life sciences sector. Biological reagents are produced for research applications, encompassing primary and secondary antibodies, immunoassay kits, cellular imaging tools, biochemical assays, proteins, peptides, proteomic tools, agonists, antagonists, activators, inhibitors, lysates, and miRNA assays. Operations focus on supporting scientific investigations through these specialized products.
- Headquarters Cambridge, United Kingdom
- Founders Avner Dahan, Tony Kouzarides
- Stage Acquired
- SectorsHealthcare
- Website category Science and Education · Biology
- Website abcam.com
- Social LinkedIn X Facebook YouTube
- Acquired by Danaher (Aug 2023)
- Legal Name Abcam Limited
- Date of Incorporation 12 Feb, 1998
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
- Total Equity Funding$78.8M (USD)
in 6 rounds
- Latest Funding Round$258.66M (USD), Debt – Conventional
May 2019
- InvestorsDanaher
& 2 more
- Investments & AcquisitionsAscent Scientific
& 11 more
- Acquired byDanaher
(Aug 2023)
Products & Services of Abcam
Abcam offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.
Antibodies for detecting specific proteins in biological samples
Kits for measuring proteins and analytes in research assays
Gene-edited cells for experimental and therapeutic studies
Apps and channels of Abcam
its YouTube channel Abcam has 2.43K subscribers and 30 videos.
Videos from Abcam
The most watched videos on Abcam's YouTube channel, Abcam (2.43K subscribers). Click a video to play it here.
More on Abcam.
Funding Insights of Abcam
Abcam has successfully raised a total of $78.8M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $258.66 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.8M
- Total Rounds 6
- Last Round Debt – Conventional — $258.66M
- First Round $799,858
(Aug 2009)
- Investors Count 2
All 6 funding rounds of Abcam with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $258.66M | Debt – Conventional | – | – | – |
| Jul 2013 | $1.28M | Grant | – | – | |
| Apr 2012 | $77M | Private Equity Round | – | – | – |
| Feb 2012 | $1.53M | Grant | – | – | |
| Jun 2011 | $1.8M | Series A | – | – | – |
| Aug 2009 | $799,858 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Abcam
Abcam has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Danaher, HHS and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Dental equipment and medical instruments are manufactured for therapeutic areas. | 1969 | danaher.com |
Investor details for Abcam
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abcam
117 people are tracked at Abcam (33 in leadership, 1 in board & advisors, 83 in team).
| Name | Role | Group |
|---|---|---|
Avner Dahan | Co-Founder | Leadership |
Tony Kouzarides | Co-Founder | Leadership |
Fiona Harlan | Head Of Assay Operation | Leadership |
Benjamin Holt | Finance Director, Supply Chain & Manufacturing And R&d | Leadership |
Bhupesh Shah | Finance Business Partner | Leadership |
Melissa Maribito | Head Of Demand Management | Leadership |
Kazi A. | Director Digital Supply Chain And Manufacturing Products | Leadership |
Nicole Nichols | HR Business Partner, Supply Chain & Manufacturing + R&d | Leadership |
Candice Hou | Strategic Marketing Director | Leadership |
Sarah Dolny | Marketing Director | Leadership |
Viorel Catalin Vasile | Finance Business Partner | Leadership |
David Kozlosky | Director Of Sales | Leadership |
Emma Billinge | Senior Director, Brand And Comms | Leadership |
Jaime Robinson | Director Of Global Events | Leadership |
Stefan Pritchard | Senior Director, Digital Commerce | Leadership |
Tiffany Shoffner | Director Of Inside Sales | Leadership |
Leanne Hayes | EMEA Sales Director | Leadership |
Josie Maydon | Director Of Talent And Engagement | Leadership |
Chelcie Eller | Director Assay Development | Leadership |
Glen Marszalowicz | Director Of Strategic Partnerships | Leadership |
97 more people are available in the full profile.
Complete people profiles for Abcam
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abcam
Abcam has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Ascent Scientific, AxioMx and BioVision.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops assay kits, antibodies, proteins & enzymes, and other research tools. | biovision.com | Milpitas, United States | 1999 | Aug 2021 | $340M | |
Develops kits and reagents for research application | markergene.com | Eugene, United States | 1993 | Mar 2020 | •••• | |
Antibody labeling and bioconjugation kits are developed and marketed. | innovabiosciences.com | Cambridge, United Kingdom | 2002 | Nov 2019 | •••• | |
Specializes in immunoassay technology | tgrbio.com | Adelaide, Australia | 2001 | Nov 2019 | •••• | |
Reagents and kits for protein-based research are developed and supplied. | expedeon.com | Swavesey, United Kingdom | 2003 | Nov 2019 | •••• | |
Age-related disorders are addressed through senescent biology research. | calicolabs.com | San Francisco, United States | 2013 | Jan 2019 | •••• | |
Custom rabbit monoclonal antibodies are developed for research applications. | calicobio.com | Pleasanton, United States | 2012 | Jan 2019 | •••• | |
A recombinant antibody discovery and development platform is operated. | axiomxinc.com | Branford, United States | 2012 | Nov 2015 | $45M | |
Develops platform to allow multiplexed assays on standard laboratory instrumentation | fireflybio.com | Cambridge, United States | 2010 | Jan 2015 | $27.98M | |
Monoclonal antibody technology and products are developed by Epitomics. | epitomics.com | Burlingame, United States | 2001 | Mar 2012 | $155M |
Complete acquisition details for Abcam
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abcam
15 dated milestones of Abcam across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Abcam is founded.
- Funding First funding round of $800K.
- Acquisition Acquires Epitomics.
- Acquisition Acquires Firefly BioWorks.
- Acquisition Acquires AxioMx.
- Acquisition Acquires Calico Labs.
- Acquisition Acquires Calico Biolabs.
- Funding Latest funding round, Debt – Conventional, of $258.7M.
- Acquisition Acquires Expedeon.
- Acquisition Acquires TGR BioSciences.
- Acquisition Acquires Innova Biosciences.
- Acquisition Acquires Marker Gene Technologies.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires BioVision.
- Exit Acquired by Danaher.
Web traffic of Abcam
The website of Abcam (abcam.com) receives about 602.8K visits a month and ranks #91,958 among all websites worldwide, #5,865 in Biology.
- Monthly visits602.8K
▲ 8.8% vs previous month
- Unique visitors245.7K
per month
- Global rank#91,958
among all websites
- Category rank#5,865
Science and Education · Biology
- Bounce rate50%
- Pages per visit2.6
- Average visit1 min 52 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with Abcam. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellsignal.com | 100% | 488.2K | #114,694 | View details | |
| rndsystems.com | 95% | 349K | #159,292 | View details | |
| novusbio.com | 93% | 199.6K | #232,152 | View details | |
| scbt.com | 91% | 444.3K | #138,937 | View details | |
| biocompare.com | 80% | 244.1K | #187,636 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Abcam
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
2 companies that operate in the same segment as Abcam (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abcam
Complete news archive for Abcam
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abcam
Abcam was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Abcam is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Abcam is a funded company, having raised a total of $78.8M across 6 funding rounds to date. The company's 1st funding round was a Grant of $799.86K, raised on Aug 2009.
Abcam was founded in 1998 in Cambridge, United Kingdom, within the life sciences sector. Biological reagents are produced for research applications, encompassing primary and secondary antibodies, immunoassay kits, cellular imaging tools, biochemical assays, proteins, peptides, proteomic tools, agonists, antagonists, activators, inhibitors, lysates, and miRNA assays. Operations focus on supporting scientific investigations through these specialized products.
Abcam offers Primary Antibodies, ELISA Kits, and Cell Lines.
Abcam has made 12 acquisitions, including Ascent Scientific, AxioMx, and BioVision.
Abcam has 3 investors. Key investors include Danaher, HHS, and National Science Foundation.
Abcam operates through Abcam Limited.
Yes. Abcam was acquired by Danaher in August 2023.
The website of Abcam receives about 603 thousand visits a month and ranks #91,958 among all websites worldwide.